A report from the American Heart Association Scientific Sessions 2012 (November 3-7 - Los Angeles, California, USA).
Highly impacting oral and poster presentations wherein new treatment modalities for coronary artery disease, heart failure and other common cardiovascular diseases were presented throughout the AHA Scientific Sessions 2012, including new developments in the area of lipid-modifying therapies that starred one of the high-impact late-breaking clinical trial sessions during the conference. A summary of the most relevant findings among the over 4,000 abstracts presented during the meeting are reported in the following report.
Thomson Reuters, Barcelona, Spain. xavier.rabasseda@thomsonreuters.com
X
X
Rabasseda
D000572:American Heart Association; D006348:Cardiac Surgical Procedures; D002317:Cardiovascular Agents / Q000627:therapeutic use*; D002318:Cardiovascular Diseases / Q000175:diagnosis / Q000209:etiology / Q000628:therapy*; D006801:Humans; D000960:Hypolipidemic Agents / Q000627:therapeutic use; D012307:Risk Factors; D016896:Treatment Outcome; D014481:United States
D002317:Cardiovascular Agents; D000960:Hypolipidemic Agents